Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36045524/
Type 2 diabetes mellitus (T2DM) is one of the main causes of mortality and morbidity worldwide. It leads to various long-term complications such as diabetic nephropathy. Diabetes nephropathy is the leading cause of renal failure in patients with chronic kidney diseases undergoing hemodialysis. Hence ...
Conclusions: Sodium-glucose cotransporter 2 inhibitor of empagliflozin is a potent anti-hyperglycemic agent. In addition, it has been shown to have some pharmacologic potentials to provide renoprotective effects in patients with T2DM. In current study, we review the available clinical data on the potential renoprotective effects of this drug from a mechanistic and molecular viewpoint.